Global banking giant Standard Chartered has released groundbreaking price predictions for Avalanche (AVAX), projecting a massive 1,200% surge to $250 by 2029. This bullish forecast positions AVAX to potentially outperform both Bitcoin and Ethereum in the coming years, according to the bank’s latest digital asset research.
In an analysis that aligns with recent institutional price targets for major cryptocurrencies, Standard Chartered’s research team has outlined an ambitious growth trajectory for AVAX, currently trading around $20.
Standard Chartered’s AVAX Price Milestones
- 2025: $55
- 2026: $100
- 2027: $150
- 2028: $200
- 2029: $250
Technical Catalysts Behind the Forecast
Geoffrey Kendrick, Standard Chartered’s global head of digital assets research, highlighted the Etna upgrade (Avalanche9000) as a game-changing development. The December 2024 upgrade has dramatically reduced subnet launch costs from $450,000 to near-zero, catalyzing a 40% surge in developer activity.
Comparative Performance Metrics
The bank’s analysis includes key ratio projections:
- BTC/AVAX ratio: Expected to decrease from 3,636 to 2,000 by 2029
- ETH/AVAX ratio: Projected to fall from 73 to 30
Bitcoin and Ethereum Projections
For context, Standard Chartered also updated its forecasts for major cryptocurrencies:
Bitcoin (BTC) Targets:
- 2025: $200,000
- 2026: $300,000
- 2027: $400,000
- 2028-2029: $500,000
Ethereum (ETH) Targets:
- 2025: $4,000
- 2026: $5,000
- 2027: $6,000
- 2028-2029: $7,500
Frequently Asked Questions
Why is Standard Chartered bullish on Avalanche?
The bank cites Avalanche’s superior scaling solution, reduced infrastructure costs, and growing developer adoption as key factors driving their positive outlook.
What risks could affect this price prediction?
Market volatility, regulatory changes, and competition from other Layer 1 protocols could impact AVAX’s growth trajectory.
How does this forecast compare to other institutional predictions?
Standard Chartered’s projection is among the most bullish institutional forecasts for AVAX, significantly exceeding current market consensus.